Is afamelanotide the same as Melanotan I?

Chemically yes: afamelanotide is [Nle4-D-Phe7]-alpha-MSH, the same molecule historically called Melanotan I. The difference is context: afamelanotide is a regulated implant for EPP, whereas Melanotan I usually refers to unregulated products sold online for tanning.

How is afamelanotide given?

In its approved use it is a subcutaneous slow-release implant inserted by a trained clinician, typically every two months during high-sunlight periods. It is not a self-injected or over-the-counter product.

Does afamelanotide make your skin darker?

Yes. It stimulates eumelanin production via MC1R, so generalized skin darkening is an expected effect and part of how it provides photoprotection in EPP.

Is afamelanotide safe for cosmetic tanning?

It is not approved or studied for cosmetic tanning. Because it increases pigmentation and can mask changes in moles, its long-term skin-cancer safety in that setting is unknown, and any such use is off-label and unmonitored.

EMA-approvedaka Scenesse, Melanotan-I, NDP-α-MSH

Afamelanotide — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Afamelanotide (also known as Scenesse) is a peptide catalogued under Cognitive & Nootropic (MC1R agonist). It is described as: MC1R agonist. Documented context: Erythropoietic protoporphyria. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Afamelanotide?

Afamelanotide (brand name Scenesse) is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), chemically [Nle4-D-Phe7]-alpha-MSH, delivered as a subcutaneous slow-release implant.

It is approved by the US FDA (2019) and the European Medicines Agency (2014) to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP), a rare inherited disorder.

Evidence is human and relatively strong for its narrow approved indication: a pivotal randomized controlled trial plus multi-year observational cohorts; it is not approved or evidence-based for cosmetic tanning or other uses.

How does Afamelanotide work?

Afamelanotide binds and activates the melanocortin-1 receptor (MC1R) on melanocytes, stimulating production of the photoprotective pigment eumelanin independently of UV exposure.

The resulting increase in skin eumelanin is thought to reduce phototoxic tissue damage in EPP by absorbing and scattering light and quenching reactive oxygen species.

What does the research say about Afamelanotide?

In a phase 3 randomized trial, adults with EPP receiving afamelanotide implants had more pain-free time in direct sunlight than those receiving placebo. ^[1]
A long-term observational study of 115 EPP patients reported sustained increases in tolerated light exposure and improved quality of life over repeated treatment cycles. ^[2]
A three-year observational study found increased phototoxic-burn tolerance time and better quality-of-life scores in EPP patients treated with afamelanotide. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Afamelanotide for Erythropoietic Protoporphyria — Langendonk JG et al., New England Journal of Medicine 2015. (Phase 3 randomized controlled trial)
[2] Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria — Biolcati G et al., British Journal of Dermatology 2015. (Long-term observational cohort)
[3] Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide - a three years observational study — Barman-Aksozen J et al., Orphanet Journal of Rare Diseases 2020. (Observational cohort, 3 years)
[4] Afamelanotide: A Review in Erythropoietic Protoporphyria — Kim ES et al., American Journal of Clinical Dermatology 2016. (Narrative drug review)
[5] Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders — Minder EI et al., Clinical Pharmacokinetics 2017. (Pharmacology review)
[6] Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria — Wensink D et al., Expert Review of Clinical Pharmacology 2021. (Narrative review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In its approved use, afamelanotide is administered only by a trained healthcare professional as a 16 mg subcutaneous implant placed roughly every two months during periods of high sunlight.

This is regulatory and clinical context, not personal dosing advice; dosing decisions belong to a prescribing physician managing an EPP diagnosis.

Side effects & safety profile

In EPP trials the most common adverse effects were generally mild and included nausea, headache, fatigue, and skin or implant-site reactions; the drug causes generalized skin darkening by design.

Because afamelanotide increases pigmentation and can obscure or alter naevi, regular full-skin and mole monitoring is advised, and it is contraindicated in significant hepatic impairment.

Long-term melanoma-risk data remain limited, so it should only be used under specialist supervision in monitored EPP centers; it is not a substitute for standard photoprotection.

Stacking & combinations

There is no evidence base for combining afamelanotide with other peptides or performance compounds, and such off-label stacking falls entirely outside its approved specialist indication.

Finding Afamelanotide vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

Yes, but only for a narrow use: increasing pain-free light exposure in adults with erythropoietic protoporphyria (EPP). The EMA approved it in 2014 and the FDA in 2019. It is not approved for tanning or any cosmetic purpose.

References

[1] Afamelanotide for Erythropoietic Protoporphyria — Langendonk JG et al., New England Journal of Medicine 2015. PMID: 26132941. View sourceStudy: Phase 3 randomized controlled trialAfamelanotide implants increased pain-free sun-exposure time versus placebo in adults with EPP.
[2] Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria — Biolcati G et al., British Journal of Dermatology 2015. PMID: 25494545. View sourceStudy: Long-term observational cohortRepeated afamelanotide treatment sustained increased light tolerance and improved quality of life in EPP.
[3] Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide - a three years observational study — Barman-Aksozen J et al., Orphanet Journal of Rare Diseases 2020. PMID: 32811524. View sourceStudy: Observational cohort, 3 yearsAfamelanotide increased phototoxic-burn tolerance time and quality-of-life scores over three years.
[4] Afamelanotide: A Review in Erythropoietic Protoporphyria — Kim ES et al., American Journal of Clinical Dermatology 2016. PMID: 26979527. View sourceStudy: Narrative drug reviewReviews efficacy and safety supporting afamelanotide's approved EPP indication.
[5] Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders — Minder EI et al., Clinical Pharmacokinetics 2017. PMID: 28063031. View sourceStudy: Pharmacology reviewSummarizes the PK/PD profile and MC1R-mediated photoprotective mechanism of afamelanotide.
[6] Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria — Wensink D et al., Expert Review of Clinical Pharmacology 2021. PMID: 33507118. View sourceStudy: Narrative reviewReviews the role of afamelanotide in preventing phototoxicity in EPP.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.